| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
44 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
27 |
| Net Income (TTM) (Millions $) |
-94 |
| Cash Flow (TTM) (Millions $) |
103 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
VectivBio Holding AG is a Swiss clinical-stage biotechnology company focused on developing innovative therapies for the treatment of severe rare diseases. The company aims to address areas of high unmet medical need and improve the lives of patients with debilitating conditions.
VectivBio is primarily dedicated to advancing its lead product candidate, apraglutide, which is being developed for the treatment of short bowel syndrome (SBS). SBS is a rare gastrointestinal disorder characterized by impaired absorption of nutrients due to the surgical removal of a significant portion of the small intestine.
Apraglutide is a novel, long-acting synthetic GLP-2 analog that has shown promise in early clinical trials for SBS patients. The drug works by promoting the repair and growth of the intestinal mucosa, thereby improving nutrient absorption and reducing dependence on parenteral nutrition.
VectivBio is also exploring the potential of apraglutide for the treatment of other rare gastrointestinal diseases, including pediatric SBS and intestinal failure-associated liver disease (IFALD).
The company's vision is to become a leading global biotech company dedicated to developing transformative therapies for severe rare diseases. With a focus on precision medicine and patient-centric approaches, VectivBio aims to make a meaningful impact on the lives of patients suffering from these debilitating conditions.
Company Address: Aeschenvorstadt 36 Basel 4051
Company Phone Number: 615513030 Stock Exchange / Ticker: NASDAQ VECT
|
%